Effect of Daily Oral Administration of Salmon Milt Peptides on Postprandial Blood Glucose Level: Placebo-controlled Double Blind Cross Over Clinical Trial

Not Applicable

• Conditions: Healthy adults

• Registration Number: JPRN-UMIN000024976
• Lead Sponsor: Hokkaido Information University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-24
• Study Completion: 2017-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects who are under treatment and medication for diabetes and dyslipidemia. 2.Subjects whose HbA1c>=6.5% 3.Subjects whose FBG>=126 mg/dl. 4.Subjects whose BFP>=40% 5.Subjects with serious disease and infection. 6.Subjects with clinical history of gastrointestinal surgery. 7.Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. 8.Subjects with serious anemia. 9.Subjects with frequent complaints of post-menopausal symptoms. 10.Subjects with a history of allergy to medicine and food, especially salmon. 11.Subjects regularly take medicine, functional foods and/or supplements which would affect glucose metabolism. 12.Subjects regularly take medicine, functional foods and/or supplements which would affect lipid metabolism. 13.Subjects who are heavy smokers and alcohol addicts, or subjects with irregular lifestyle. 14.Subjects who donated either 400 ml whole blood within 12 weeks (men) /16 weeks (women) or 200 ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 15.Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the study. 16.Subjects who participate in other clinical trials within the last 4 weeks prior to the current clinical trial. 17.Subjects who are not eligible due to physician's judgment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FBG at baseline and at 30 min, 60 min, 90 min, 120 min after oral glucose load, and AUC.

Secondary Outcome Measures

Name	Time	Method
Fasting Insulin level at baseline and at 30 min, 60 min, 90 min, 120 min after oral glucose load, and AUC.